Research programme: Alzheimer's disease therapeutics - Pain Therapeutics

Drug Profile

Research programme: Alzheimer's disease therapeutics - Pain Therapeutics

Alternative Names: PTI-125

Latest Information Update: 09 Jun 2017

Price : $50

At a glance

  • Originator Pain Therapeutics
  • Class Antidementias; Small molecules
  • Mechanism of Action Microfilament protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 05 Jun 2017 Pain Therapeutics announces intention to submit an IND application with the US FDA for PTI 125, in the third quarter of 2017
  • 01 Jun 2017 Pharmacodynamics data from a preclinical trial in Alzheimer's disease released by Pain Therapeutics
  • 18 Jul 2012 Preclinical trials in Alzheimer's disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top